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 2 
Abstract  1 
In this paper we compare experiences of seven industrialized countries in considering 2 
approval and introduction of the world’s first cervical cancer-preventing vaccine. 3 
Based on case studies, articles from public agencies, professional journals and 4 
newspapers we analyse the public debate about the vaccine, examine positions of 5 
stakeholder groups and their influence on the course and outcome of this policy 6 
process. The analysis shows that the countries considered here approved the vaccine 7 
and established related immunization programs exceptionally quickly even though 8 
there still exist many uncertainties as to the vaccine’s long term effectiveness, cost-9 
effectiveness and safety. Some countries even bypassed established decision-making 10 
processes. The voice of special interest groups has been prominent in all countries, 11 
drawing on societal values and fears of the public. Even though positions differed 12 
among countries, all seven decided to publicly fund the vaccine, illustrating a 13 
widespread convergence of interests. It is important that decision-makers adhere to 14 
transparent and robust guidelines in making funding decisions in the future to avoid 15 
capture by vested interests and potentially negative effects on access and equity. 16 
 17 
Keywords (3-6): Vaccination; Human Papillomavirus; Decision Making; Public 18 
Health; Pharmaceutical Policy; Public Policy 19 
 20 
1. Introduction 21 
“It took 15 years for Gardasil to make a national hero of its creator, Ian Frazer. But it 22 
took just three days for the world's first cancer-preventing vaccine to make a national 23 
dill of federal Health Minister Tony Abbott. […] John Howard, alert as ever to the 24 
public mood, delivered sparkling prime ministerial endorsement to Gardasil along 25 
 3 
with a clear direction to Minister Abbott that the immunisation program should 26 
proceed. And pronto.” [1]  27 
 28 
“[T]he public, as well as policy makers, must be provided with sound and 29 
comprehensive multidisciplinary evidence for vaccination as well as unbiased data 30 
about the potential benefits and harms expected from widespread immunization with 31 
the HPV vaccine, and all this information must come before governments allocate 32 
huge sums of already limited health care dollars to such programs. Individual girls 33 
and women, as well as policy makers, can only make truly informed decisions about 34 
vaccinations when they have all the evidence. At this point in time, there are more 35 
questions than answers.” [2, p.16] 36 
 37 
In this paper, we analyze and compare the experiences of seven countries (Australia, 38 
Canada, Denmark, Germany, New Zealand, Switzerland and the U.S.) in considering 39 
the world’s first cervical cancer-preventing vaccine and making a decision about its 40 
introduction and/or funding. The above quotations nicely illustrate two characteristics 41 
of this process. First, on the whole, the countries considered here approved the HPV 42 
vaccine and related programs with marked haste, some circumventing established 43 
channels and procedures in the process. Second, public debates ensued in many 44 
countries, fuelled by uncertainties about the duration of the vaccine’s efficacy and the 45 
precise nature of the link between HPV and cervical cancer. Because vaccine 46 
programs are still new, the rate of the HPV vaccine’s uptake—and its impact on 47 
routine Pap test utilization—remains largely to be determined. With respect to the 48 
establishment of such programs, however, our analysis suggests that countries with 49 
different decision-making processes can arrive at a similar decision about the value of 50 
 4 
a health policy or program, a pattern that reflects the influence of a particularly strong 51 
and ubiquitous set of political pressures at work.   52 
 53 
2. Materials and methods 54 
The International Network Health Policy and Reform1 convenes experts from 20 55 
countries to report on and compare health policy processes from around the 56 
industrialized world. In 2007, several countries in the Network reported on the 57 
introduction of a human papillomavirus (HPV) vaccine for the prevention of cervical 58 
cancer. The almost simultaneous consideration and adoption of this particular policy 59 
issue in several countries provides a unique opportunity to compare in detail the 60 
relevant policy processes and outcomes. Here we use Network member case studies 61 
[3-8] from six of the seven countries mentioned above as well as publications by 62 
public agencies, in journals and newspapers to examine the debate about the vaccine 63 
and the actors who influenced the debate and its outcome. For Denmark we only 64 
employed the latter resources [9-14]. 65 
 66 
3. Human Papillomavirus and the development of a vaccine 67 
Worldwide, cervical cancer is the second or third most common cancer among 68 
women; nearly half a million women are diagnosed with and more than 270,000 die of 69 
the disease each year [15, 16]. Cervical cancer is a rare outcome of a fairly common 70 
infection with HPV. Of the more than 100 HPV strains that infect humans, only a few 71 
                                                 
1 Since 2002 the International Network Health Policy and Reform has brought together health policy 
experts from around the world to report on current health reform issues and health policy developments 
in their countries. In two survey rounds per year, Network members report up to five health policy 
issues using a questionnaire aimed at describing and analysing the dynamics or the processes of the 
policy or policy proposal under review. Although members are experts in policy research, their reports 
are based on expert assessment, not the results of structured research. All reports are available on the 
Network’s website www.healthpolicymonitor.org 
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are linked to cervical cancer; most low- and high-risk HPV infections spontaneously 72 
regress [17, 18].  73 
 74 
Nonetheless, the establishment of a viral cause of cervical cancer paved the way for 75 
the development of a vaccine with the potential to prevent this cancer [19, 20]. In 76 
1991, investigators at the University of Queensland found a way to form non-77 
infectious virus-like particles (VLPs) that strongly activated the immune system. In 78 
1993, a laboratory at the U.S. National Cancer Institute generated the VLPs that 79 
formed the basis for the HPV16 component of the first cervical cancer vaccine, 80 
Gardasil, which was jointly developed by Sanofi-Pasteur and Merck. Later, 81 
GlaxoSmithKline developed its own cervical cancer vaccine, Cervarix. 82 
 83 
Both Gardasil and Cervarix target HPV types 16 and 18, which together cause more 84 
than 70% of all cervical cancers [21]. (Neither vaccine prevents 100% of cervical 85 
cancers.) Gardasil also targets HPV types 6 and 11, which cause genital warts. Three 86 
doses of the vaccine are required (at 0, 1 and 6 months), and the duration of protection 87 
appears to be at least five years. As HPV is easily transmitted and most infections 88 
occur soon after a woman first becomes sexually active, the vaccines are most 89 
effective if administered prior to the commencement of sexual activity. Widespread 90 
use of the vaccines is expected to reduce the incidence of cervical cancer; however, 91 
women who receive the vaccine will continue to need regular Pap screening because 92 
neither vaccine protects against all oncogenic HPV types and because the duration of 93 
protection remains uncertain [22]. The European Commission also recommends that 94 
authorities carry out population-wide, quality assured cervical screening by pap smear 95 
 6 
(according to the EU guidelines) before introducing HPV vaccination into the 96 
population [3]. 97 
 98 
4. Comparing and contrasting the approval process 99 
In all seven countries considered here, the vaccine was approved for use in 2006 and 100 
made available to women as a three-dose schedule for between 292 PPP-$ and 527 101 
PPP-$2 (see also table 1). Although there was debate in the scientific community 102 
about issues of safety and efficacy in connection with the approval process, the public 103 
debate, which is the subject of this paper, occurred during and after policy processes 104 
concerned with developing or implementing subsidized vaccination programs were 105 
commenced. 106 
 107 
In Canada, Gardasil was approved for use in the summer of 2006. Following advice 108 
from Canada’s National Advisory Committee on Immunisation that the vaccine’s high 109 
cost was preventing its adoption, the Canadian government approved CAN$300m 110 
(248m PPP-$) in new funding to the provinces to provide free vaccination to girls 111 
aged 9 to 13 [8]. By June 2008, five provinces had adopted a free vaccination 112 
program, and all ten provinces have now approved voluntary school-based programs. 113 
Implementation of the vaccination program has been accompanied by media and 114 
professional articles questioning the wisdom of the free vaccination program in light 115 
of ongoing concerns about the vaccine’s necessity [23]. It has also been reported that 116 
this is the most expensive vaccination program ever introduced in Canada [24].   117 
 118 
                                                 
2 In this paper, all costs were converted using 2007 OECD purchasing power parities (see 
http://www.oecd.org/dataoecd/61/56/39653523.xls). 
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In October 2007, Denmark’s National Board of Health recommended HPV 119 
vaccination for girls at the age of 12 as a component of the general-tax financed child 120 
vaccination program [13]. In addition, a two-year catch-up program was 121 
recommended for girls aged 13 to 15 years; both recommendations were based on an 122 
evaluation by the Danish Centre for Health Technology Assessment [12]. The 123 
government obtained broad acceptance for the introduction of the program towards 124 
the end of 2007, but financing of the program was debated, and a parliamentary 125 
election delayed the final decision until early 2008. The program, set to start in 2009, 126 
is being financed through a reduction in public support for other pharmaceuticals, a 127 
fact that cost the program the support of the Social Democratic and Socialist parties. 128 
The program’s funded product is Gardasil, which was selected because it also protects 129 
against genital warts. 130 
 131 
In New Zealand, most pharmaceuticals are subjected to a systematic review process 132 
by an independent government entity, Pharmac, for the purposes of public funding. 133 
Vaccination programs, however, fall outside of this review process; decisions are 134 
instead made by the Ministry of Health. In November 2006, the Ministry ignored the 135 
advice of its Therapeutic Advisory Group when it decided not to fund the vaccine, 136 
citing insufficient information about its long-term efficacy, impact on health 137 
inequalities and cost-effectiveness [25]. However, the decision was reversed in May 138 
2008, when the Minister of Health announced that an “interim” program would 139 
provide free Gardasil vaccinations for teenagers up to age 18 who are not at school, 140 
beginning in September 2008, followed by a national program for girls aged 12 to 13 141 
years starting in 2009 [6].  142 
 143 
 8 
In Germany, the Standing Vaccination Committee (STIKO) recommended in March 144 
2007 that all girls aged 12 to 17 be immunized. Some sickness funds swiftly included 145 
the HPV vaccine in their benefit baskets and heavily marketed it to compete for 146 
members. Only a few months earlier, however, the funds criticized the part of the 147 
2007 health reform bill—enacted in April 2007—that would oblige them to 148 
automatically cover vaccinations recommended by STIKO (including standard safe 149 
childhood vaccinations), fearing additional immunization-related costs of up to €1.6 150 
billion (1.8 billion PPP-$). Since the 2007 reform that placed new emphasis on 151 
effective prevention, some states have launched programs to vaccinate girls at school, 152 
and some funds cover the immunization for women up to age 26. The decisions to 153 
recommend and fund the vaccine were initially welcomed in Germany; however, 154 
some criticism regarding vaccine safety and the efficiency of its inclusion in the 155 
benefit basket has been reported in the media [3].  156 
 157 
In Switzerland, Swissmedic, the Swiss Agency for Therapeutic Products, approved 158 
Gardasil in November 2006. In June 2007, the Federal Commission for Vaccination 159 
recommended that girls aged 11 to 14 (and girls aged 15 to 19 in a five year 160 
“transition program”) be vaccinated within the scope of the country’s mandatory 161 
health insurance [26]. However, responsibility for formal reimbursement decisions 162 
with respect to the benefit basket rests with the Federal Department of Home Affairs, 163 
which politically endorses the final recommendation by the federal benefit basket 164 
commission; the decision on Gardasil took several months. In summer 2007, three 165 
cantonal departments of public health—Geneva, Valais and Basel Land—decided to 166 
finance the HPV vaccination out of fiscal funds and started a pilot vaccination project 167 
in their schools. Their action placed strong political pressure on the federal benefit 168 
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basket commission [4], which granted formal reimbursement approval in November 169 
2007. Since January 2008, mandatory health insurance has covered HPV vaccination, 170 
as long as it is carried out within a formal vaccination program designed at cantonal 171 
level [27]. 172 
 173 
In the U.S., Gardasil was reviewed and endorsed by the federal Advisory Committee 174 
on Immunization Practices (ACIP) in 2006. The Committee recommended that girls 175 
aged 11 to 12 be vaccinated and that girls and young women aged 13 to 26 be 176 
vaccinated using a “catch-up” approach. The committee also determined that the 177 
vaccine should be made available through Vaccines for Children, a federal program 178 
that makes immunizations available to children from low-income families. State 179 
legislatures, which determine school vaccination requirements, typically rely on 180 
ACIP’s findings when considering whether to require a vaccine for school enrolment. 181 
In 2006 and 2007, more than two dozen states considered legislation to make HPV 182 
vaccination a requirement for girls’ school entry. However, most bills met with strong 183 
resistance, and only in Virginia was a school mandate approved and signed into law. 184 
In several states, such as California, school mandates were ultimately removed from 185 
HPV-related legislation. In nearly every state where mandate bills were introduced, 186 
vaccine-related legislative activity has been dogged by questions about the safety and 187 
long-term effects of the vaccine as well as controversy over the manufacturer’s role in 188 
the political process [5]. 189 
 190 
In Australia, the vaccine was approved for use by the Therapeutic Goods 191 
Administration (TGA) in June 2006. However, in early November 2006, the 192 
Pharmaceutical Benefits Advisory Committee (PBAC) rejected an application by the 193 
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manufacturer of the vaccine to list it on the Pharmaceutical Benefits Schedule (PBS) 194 
on the grounds that it was not cost-effective. Typically, a revised application would be 195 
submitted to a subsequent meeting of the PBAC, but the committee was not scheduled 196 
to meet until March 2007. The Australian government supported the inclusion of the 197 
vaccine on the PBS and encouraged discussions between the Department of Health 198 
and Ageing and the manufacturer to reduce the price of the vaccine. At the end of 199 
November 2006, the PBAC convened a special meeting, at which it approved the 200 
vaccine for listing on the PBS. In 2007, a program of school vaccination was 201 
introduced for girls aged 13, together with a catch-up program for girls aged 14 to 17. 202 
The two-year catch-up program is also available to women aged 18 to 26, who can 203 
receive the vaccination free from their general practitioner [7]. 204 
 205 
Table 1 “Year of introduction or public funding for HPV vaccine and target groups” 206 
approximately here 207 
 208 
5. Influencing the policy debate 209 
5.1 Role of the manufacturers 210 
In countries with a pharmaceutical industry, manufacturers adopt practices designed 211 
to enhance the chances of their product being recommended, approved or subsidized. 212 
Such practices include employing lobbyists, engaging the media, and identifying 213 
potentially supportive groups within the community. In this case, the presence of the 214 
manufacturer was more obvious in some countries than in others, and its public 215 
profile varied. In Canada, Germany and the U.S., public perception that Merck, Sharp 216 
and Dohme was “leading” the push for a subsidized program, as well as the perceived 217 
influence of the company on politicians and community groups, may have played a 218 
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role in the growth of substantial opposition to the vaccine. In the U.S., for instance, 219 
the local media reported on the Texas governor’s ties to a Merck lobbyist and on a 220 
California lawmaker’s ownership of Merck stock. In Germany, a perceived lack of 221 
independence and transparency by STIKO and the connection between STIKO and 222 
the pharmaceutical industry were implied by the opposition Green party in parliament 223 
and also featured in the public debate [28, 29]. 224 
 225 
The pharmaceutical companies’ public profiles were markedly different in Denmark 226 
and Australia during the course of the policy process. In Denmark, one 227 
pharmaceutical company, Sanofi Pasteur MSD, employed the media to generate 228 
political debate about inequities in access to the vaccine, while the other, 229 
GlaxoSmithKline, resisted the decision to fund only a vaccine that also protected 230 
against genital warts. In Australia, meanwhile, the manufacturer’s role was much less 231 
obvious; the widespread media coverage prior to and following the PBAC’s initial 232 
decision portrayed the vaccine in a generally favourable light and it received strong 233 
political support from both government and opposition parties [30]. Media interest in 234 
the vaccine was particularly enhanced by the central role played by University of 235 
Queensland researchers in its development. One of the leaders of this research, 236 
Professor Ian Frazer, was named Australian of the Year in 2006 and was featured in 237 
the media personally administering the first publicly available injection of the vaccine 238 
in Australia. The presence of such a credible opinion leader is likely to have had a 239 
powerful influence on the debate in Australia. 240 
 241 
5.1.1 Marketing the HPV vaccine 242 
 12 
Direct-to-consumer advertising (DTCA) of drugs is permitted only in two of the case 243 
countries, New Zealand and the U.S. (in fact, New Zealand and the U.S. are the only 244 
industrialized countries worldwide that allow DTCA for prescription drugs). In New 245 
Zealand, Gardasil was not prominently advertised by the manufacturer following its 246 
approval. And while the New Zealand government may have liked to have advertised 247 
the launch of the vaccination program, its recently-passed Electoral Finance Act 248 
constrained its ability to do so during the lead-up to the election [31].  249 
 250 
In the U.S., Gardasil has been marketed directly to consumers, particularly teenage 251 
girls and their mothers. Marketing efforts have focused heavily on the vaccine’s 252 
potential to prevent cancer. Prior to Gardasil’s approval, Merck sponsored a national 253 
campaign to promote awareness of the link between HPV and cervical cancer. A 254 
second campaign, launched after Gardasil’s approval, urged adolescent girls to be 255 
“one less” victim of cervical cancer. 256 
 257 
5.2 Special interest groups  258 
Special interest groups, such as medical associations and consumer advocacy groups, 259 
play an important role in the public debate about policy proposals. In Canada, New 260 
Zealand, Australia and the U.S., most medical and public health agencies and 261 
societies supported a voluntary subsidized program, although several U.S. 262 
organisations stopped short of supporting a mandatory scheme. In the North American 263 
countries and in Denmark, some medical researchers questioned the need for such a 264 
program and were concerned about the long-term safety of the vaccine [11], while 265 
others, such as the Danish Cancer Society and the American College of Obstetricians 266 
and Gynecologists, argued for expanding the vaccine’s availability [9]. 267 
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 268 
In Canada, the Women’s Health Network opposed the program [2]. Similarly, in New 269 
Zealand, Women’s Health Action expressed a number of concerns about the proposed 270 
program, including its hurried introduction, and the lack of data on the long-term 271 
efficacy of the vaccine and its effects on 11 and 12 year old girls [32]. In contrast, in 272 
Australia, a petition sponsored by women supporting an immunization program was 273 
presented to Parliament, asking that the PBAC review its initial decision. Concerns 274 
about necessity and long-term safety were conspicuously absent from the debate.  275 
 276 
In the U.S. and Canada, opposition was also voiced by social conservatives, including 277 
some church groups, and parent groups; in Australia, again, such opposition was 278 
muted. In New Zealand, medical practitioners responded to the initial decision not to 279 
fund the vaccine with an outcry [33], while the general public expressed little 280 
reaction. The precise reasons for this are obscure, but the absence of a pharmaceutical 281 
industry in New Zealand may be relevant.  282 
 283 
In the U.S., some advocates for disadvantaged groups, such as the poor or minorities, 284 
opposed the introduction of a mandatory scheme on the grounds that it would unfairly 285 
target members of their constituency with an unproven vaccine; others, meanwhile, 286 
argued that the cost of the vaccine would be prohibitive for many lower-income 287 
women. In New Zealand, the Ministry of Health expressed concerns that a vaccination 288 
program might increase inequalities if deprived populations did not achieve 289 
vaccination coverage as high as more advantaged groups [25]. 290 
 291 
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It is not surprising that a vaccine targeting a sexually transmitted disease raises moral 292 
issues, particularly as the vaccine has been shown to be most effective in girls prior to 293 
their becoming sexually active. Among the most common arguments presented in 294 
opposition to the vaccine was the argument that vaccination would encourage girls 295 
and young women to become sexually active at an earlier age, be promiscuous, or 296 
engage in sexual activity outside of marriage, because the vaccine would lead them to 297 
believe that sexual activity posed no risks. These arguments were most prominent in 298 
the U.S. and Canada, where they were raised largely by politically conservative and 299 
religious groups. They were also raised in Australia and New Zealand, but never 300 
gained prominent media coverage. In the U.S., young women themselves countered 301 
and at times echoed these arguments in a vibrant debate on the vaccine which took 302 
place in online forums.  303 
 304 
In Switzerland, a fierce public debate erupted as the cantonal vaccination programs 305 
began in the summer of 2008. Anti-vaccination lobbyists strongly opposed the 306 
programs, and a forum of paediatricians argued that the programs would violate 307 
patient privacy, because cantonal authorities proposed collecting data on HPV 308 
infected women and vaccination uptake. A consumer association warned of the risk of 309 
mass vaccination without sufficient information and suggested that girls and parents 310 
boycott the cantonal programs until a more informed decision could be made [34, 35]. 311 
Cantons, health insurers and the manufacturer negotiated a lump-sum reimbursement 312 
of 291 PPP-$ (the starting price was 429 PPP-$) for the three injections, including the 313 
physician’s fee (30 PPP-$). Vaccination should mainly occur in schools, but families 314 
are free to choose to access the program through a paediatrician, gynaecologist or GP. 315 
The involvement of private doctors is crucial for the catch-up program, but the Swiss 316 
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Society of General Medicine claimed that a payment of 10 PPP-$ per vaccination is 317 
not sufficient and recommended to its members that they boycott the cantonal 318 
vaccination programs. 319 
 320 
5.3 Political influences 321 
In New Zealand and Australia, the final decisions about implementing an HPV 322 
vaccination program were made in the context of upcoming national elections. 323 
Australia held parliamentary elections in late 2007 and New Zealand in late 2008. In 324 
New Zealand, it is not uncommon for new national health programs to be introduced 325 
just prior to a general election, an event that occurred with both the national cervical 326 
cancer and breast cancer screening programs [32].  327 
 328 
5.4 Cost-effectiveness 329 
The relevant decision-making authorities in Australia, Denmark and Switzerland 330 
considered modelled evaluations of the cost effectiveness of the vaccine, but as with 331 
all models, the results rest on assumptions which may not turn out to be representative 332 
of reality [36]. For example, two important variables are likely to be the cost of the 333 
vaccine and the rate of uptake. In Switzerland, an uptake rate of 80% and a price of 334 
143 PPP-$ per dose produced a cost per QALY gained of 15,757 PPP-$ [37]. In 335 
Denmark, the cost-effectiveness ratios of various scenarios were estimated. A base 336 
scenario with an uptake of 70%, a time horizon of 62 years, and a price of 366 PPP-$ 337 
produced a cost-effectiveness ratio of 9,993 PPP-$ per life year gained. At the other 338 
extreme, vaccinating boys3 as well as girls with a catch-up program for young people 339 
                                                 
3 There have been calls for vaccination of boys, because boys infected with HPV can pass it on to girls. 
Moreover, bisexual and gay men are at risk too. Interestingly, such a call has been made by the nobel 
laureate who worked 
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up to age 19 and with an uptake of 85% resulted in a cost-effectiveness ratio of 41,194 340 
PPP-$ [12]. In Australia, the cost-effectiveness ratios on which decisions are based 341 
are not published; the committee indicated that it recommended funding on the basis 342 
of a “high, but acceptable cost-effectiveness ratio resulting from a price reduction” 343 
[38].  344 
 345 
6. Implementation and outcomes of the policy 346 
In all countries except the U.S., HPV vaccination programs, whether delivered as a 347 
school-based program or via a health insurance package, are being offered on a 348 
voluntary basis. In the U.S., making vaccines mandatory for school enrolment is 349 
commonly accepted as a nearly foolproof means of achieving universal vaccination, 350 
but HPV vaccine mandates proved to be a failure in state legislatures across the 351 
country. More than a dozen states, however, approved related legislation, allotting 352 
funding to vaccinate school-age or low-income girls, requiring public and/or private 353 
insurers to cover the vaccine, or providing support for public education about HPV 354 
and its role in cervical cancer.  355 
 356 
Thus far, there are few data available about the rate of HPV vaccination uptake in any 357 
of the case countries. Where data are available, results are mixed. In Ontario, Canada, 358 
less than 50% of eligible girls have been vaccinated, compared to a usual acceptance 359 
rate for school-based vaccinations of 80 to 90% [39]. In Australia, a group of 360 
researchers in New South Wales (NSW) have used early coverage data to estimate 361 
that coverage in 2007/2008 will likely reach 86% (with a feasible range of 67-90%) 362 
                                                                                                                                            
on HPV(www.xtra.ca/public/National/Nobel_laureate_calls_for_HPV_vaccine_for_boys-5754.aspx). 




for girls aged 12 to 13, with lower rates in older females [40]. A family planning 363 
organization in NSW found that of 213 women who had visited a GP in the previous 6 364 
months, 59 (53.6%) of these had visited a GP specifically to have the HPV vaccine 365 
[41]. In Geneva, Switzerland, a pilot project targeting 2,000 girls, which began in fall 366 
2007, reported vaccination of 1200 girls i.e. a final uptake rate of 60% [42, 43]. 367 
Usually uptake rates for vaccination in Switzerland (in particular in the latin cantons) 368 
are higher than 80%. In a survey of 409 young women by researchers in Cincinnati, 369 
Ohio, in the U.S., 66% said they intended to get vaccinated, but just 42% said they 370 
thought they could afford the vaccine [44]. 371 
 372 
There is likewise only limited information available about the vaccine’s side effects, 373 
due to the recent implementation of programs. In Australia, by the end of June 2008, 374 
more than 3.7 million doses of Gardasil had been distributed and just over 1,000 375 
suspected adverse events had been reported (27/100,000 doses). Seventy-eight percent 376 
were mild or common problems, such as injection site reaction, headache, dizziness, 377 
nausea and vomiting; there have also been 12 reports of anaphylaxis and 91 reports of 378 
hives [45]. In the U.S., the Centers for Disease Control and Prevention reported in 379 
August 2008 that of more than 10,000 reported adverse events linked to Gardasil, 6% 380 
were considered serious, and included blood clots and Guillain Barré syndrome; 27 381 
deaths of women who received the vaccine were attributed to non-vaccine-related 382 
causes [46]. The Canadian Public Health Agency has reported that among more than 383 
500,000 doses of Gardasil distributed so far, there have been no confirmed cases of 384 
anaphylaxis and 220 less severe adverse events (44/100,000 doses) [39]. These rates 385 
are comparable to those reported, for instance, for childhood immunization in 386 
Australia for 2004, which ranged from a reporting rate of 6.3/100,000 doses for 387 
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bivalent Haemophilus influenzae type b-hepatitis B vaccine to 47.7/100,000 doses for 388 
Diphtheria-tetanus-pertussis immunisation [47] 389 
 390 
6. Discussion  391 
Although the scientific issues associated with the HPV vaccine are not unique, the 392 
case illustrates important issues associated with the interpretation of scientific 393 
knowledge for policy-making purposes. The overall objectives of a vaccination 394 
program are to reduce the morbidity and mortality associated with cervical cancer. 395 
However, the relationship between many HPV strains and morbidity and mortality is 396 
very complex and not well understood. Thus, there is, as yet, no direct scientific proof 397 
of the effect of the vaccine on morbidity and mortality, and it will take significant 398 
time and resources to obtain such evidence.  399 
 400 
There is also, thus far, no evidence of the effect vaccination programs will have on 401 
cervical cancer screening rates. Ongoing research is needed to build the evidence base 402 
for the effectiveness of the HPV vaccine; it will also be important to monitor the rate 403 
of uptake of both the vaccination and Pap tests. Delivering a “double-barrelled” public 404 
health message (for example, obtain this vaccination AND continue to receive regular 405 
Pap tests) may be less effective than the previous, simple public health message about 406 
having regular Pap tests. In Switzerland the health insurer association accepted the 407 
financing of the most expensive vaccination in Swiss history, but in exchange asked 408 
the federal benefit basket commission to increase the time between two reimbursed 409 




Although Gardasil is more expensive than most other vaccines, the question of cost-413 
effectiveness has not been a central feature of the public debate. Perhaps the focus on 414 
‘saving lives’ lost to cervical cancer overshadowed questions about cost and cost-415 
effectiveness. Whatever the reason, given the many competing demands on health 416 
funds, open discussion about the relative cost-effectiveness of the vaccine compared 417 
with other health interventions has been conspicuous for its absence from this debate. 418 
 419 
The level of uncertainty about effectiveness and uptake, in addition to questions about 420 
duration of immunity and cost-effectiveness, created the space for "struggle" between 421 
interested parties. In some countries, such as Australia and New Zealand, the level of 422 
scientific uncertainty was initially used by decision-makers as a reason for not 423 
funding the vaccine. On the other hand, once a decision to approve or fund the 424 
vaccine was made, scientific uncertainty often became a central focus of objections by 425 
interest groups opposed to vaccination proposals.   426 
 427 
The comparative analysis undertaken here shows that countries with different 428 
decision-making processes can make similar decisions about the value of subsidizing 429 
a program, even when the influence of supporters and opponents seems disparate. 430 
This could be the result of the specific socio-political environments in each country.  431 
In other words, since the science seems to be reasonably solid on the potential 432 
efficacy of an HPV vaccine, and in spite of the debate about the vaccine’s real-world 433 
effectiveness, uptake and the merits of public subsidy, countries could come to similar 434 
conclusions because those in policy decision-making roles are responding to specific, 435 
and similar, political pressures. 436 
 437 
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Another interesting—and possibly unique—feature of the HPV vaccine case is that it 438 
prompted a number of countries in this study to divert from their usual decision-439 
making processes. Few subjected the vaccine to a systematic process of review, and 440 
there seemed to be a degree of urgency among decision makers to approve the vaccine 441 
and fund organised programs. In at least two countries, Australia and New Zealand, 442 
initial decisions not to fund the vaccine were later overturned, even though no new 443 
scientific evidence had become available. One reason for this apparent urgency is 444 
clearly political; in a number of countries, decisions to fund the vaccine were made in 445 
the context of upcoming or current elections, raising questions about the extent to 446 
which political influence can override bureaucratic processes. Another reason may be 447 
that some countries are willing to be guided in their decisions by others who are 448 
perceived as leaders in pharmaceutical decision making processes. Countries with 449 
well-established decision-making processes, such as Australia, are widely perceived 450 
as credible and their lead often followed by others. There is a chance, however, that if 451 
“follower” countries are not aware of particular political or other circumstances at 452 
play in “leader” countries, their decisions may be based on factors irrelevant to their 453 
situation. 454 
 455 
7. Conclusion 456 
The speedy introduction of a subsidized vaccination program across a number of 457 
developed countries represents a convergence of interests, whether motivated by 458 
profit or public health. Lessons about how to influence the public debate and maintain 459 
pressure on bureaucrats and politicians will not have been lost on advocates and 460 
lobbyists. Supporters of vaccination programs used the values of caring (for your 461 
daughter) and prevention (of cancer) to effectively argue for the vaccine’s subsidy. 462 
 21 
Both supporters and opponents drew on fear, of cancer and promiscuity, respectively, 463 
to influence decision making. The media, not surprisingly, was deployed as an 464 
important conveyor of messages, disparate as these messages were from one country 465 
to another.  466 
 467 
Interested parties will always try to influence decisions; attempts by individuals and 468 
organisations to promote a particular agenda through the media and by directly 469 
lobbying politicians and their advisors are a well-accepted aspect of the democratic 470 
process. Increasing pressure to cover new drugs while maintaining coverage of the 471 
existing basket of products and services requires policy-makers to use transparent and 472 
robust guidelines in making funding decisions. Those guidelines should remain at 473 
arms-length from political processes. It is up to decision makers, both bureaucratic 474 
and political, to remain as firm as possible in their adherence to the agreed-upon 475 
decision-making procedures. 476 
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Table 1: Year of introduction or public funding for HPV vaccine and target 
groups  
 
Country Approval of 
vaccine and 





Target group (all girls) 
Australia June 2006 
315 $ 
(Gardasil) 
2007 Aged 13 + catch-up for those aged 
14-17yrs 
Canada July 2006 
335 $ 
(Gardasil) 
2006-2008 Aged 9-13 
Denmark October 2006 
359 $  
(Gardasil) 
2009 Aged 12 years + catch-up for those 
aged 13-14 years 
Germany September 2006 




2007 Aged 12-17, some sickness funds 







2008 School aged 12–13 years + catch-up 
for those aged up to 18 years not at 
school. 
Switzerland November 2006 2008 Aged 11-14 + catch-up for those 
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429 $  
(Gardasil) 
Since 2008: 291 $ 
aged 15-19 years 
USA June 2006  
$360 (Gardasil) 
2006 Aged 11-12 + catch-up for those 
aged 13-26 years 
 
 
